Cargando…

Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma

Background: Adrenocortical carcinoma (ACC) is a rare tumor entity with restricted therapeutic opportunities. HSP90 (Heat Shock Protein 90) chaperone activity is fundamental for cell survival and contributes to different oncogenic signaling pathways. Indeed, agents targeting HSP90 function have shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siebert, Claudia, Ciato, Denis, Murakami, Masanori, Frei-Stuber, Ludwig, Perez-Rivas, Luis Gustavo, Monteserin-Garcia, José Luis, Nölting, Svenja, Maurer, Julian, Feuchtinger, Annette, Walch, Axel K., Haak, Harm R., Bertherat, Jérôme, Mannelli, Massimo, Fassnacht, Martin, Korpershoek, Esther, Reincke, Martin, Stalla, Günter K., Hantel, Constanze, Beuschlein, Felix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658895/ https://www.ncbi.nlm.nih.gov/pubmed/31379752 http://dx.doi.org/10.3389/fendo.2019.00487

Ejemplares similares

Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation
por: Hantel, Constanze, et al.
Publicado: (2016)

Investigating the Role of Cholesterol and Lipid Trafficking in Mitotane Resistance in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2021)

Three Dimensional Models of Endocrine Organs and Target Tissues Regulated by the Endocrine System
por: Luca, Edlira, et al.
Publicado: (2023)

Metabolic heterogeneity in adrenocortical carcinoma impacts patient outcomes
por: Wang, Qian, et al.
Publicado: (2023)

Silencing Mutated β-Catenin Inhibits Cell Proliferation and Stimulates Apoptosis in the Adrenocortical Cancer Cell Line H295R
por: Gaujoux, Sébastien, et al.
Publicado: (2013)

Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications
por: Sbiera, Iuliu, et al.
Publicado: (2021)

Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma
por: Warde, Kate M, et al.
Publicado: (2022)

The Vault Complex Is Significantly Involved in Therapeutic Responsiveness of Endocrine Tumors and Linked to Autophagy under Chemotherapeutic Conditions
por: Bornstein, Stefan, et al.
Publicado: (2023)

DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma
por: Kerdivel, Gwenneg, et al.
Publicado: (2023)

SUN-LB22 PLK1 as a New Treatment Target for Adrenocortical Carcinoma
por: Smith, Gabrielle, et al.
Publicado: (2020)

Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas
por: Weigand, Isabel, et al.
Publicado: (2017)

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021)

The role of adrenal venous sampling (AVS) in primary bilateral macronodular adrenocortical hyperplasia (PBMAH): a study of 16 patients
por: Rubinstein, German, et al.
Publicado: (2022)

Combined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of β-catenin in adrenocortical carcinoma
por: Lefèvre, L, et al.
Publicado: (2015)

An update on adrenocortical cell lines of human origin
por: Sigala, Sandra, et al.
Publicado: (2022)

Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids
por: Langer, Carolin, et al.
Publicado: (2022)

Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma
por: Kimpel, Otilia, et al.
Publicado: (2022)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma
por: Liang, Raimunde, et al.
Publicado: (2020)

Past, Present and Future of Epigenetics in Adrenocortical Carcinoma
por: Ettaieb, Madeleine, et al.
Publicado: (2020)

Health-Related Quality of Life in Adrenocortical Carcinoma
por: Steenaard, Rebecca V., et al.
Publicado: (2019)

Recent advances in understanding corticotroph pituitary tumor initiation and progression
por: Renner, Ulrich, et al.
Publicado: (2018)

Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study
por: Elhassan, Yasir, et al.
Publicado: (2021)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo — challenges and prospects
por: Jakoby, Judith, et al.
Publicado: (2015)

Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment
por: Bothou, Christina, et al.
Publicado: (2021)

SUN-216 Investigating the Role of the Liver X Receptor in Potentiating Mitotane Therapy in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2020)

Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
por: Terzolo, Massimo, et al.
Publicado: (2023)

Adrenocortical Carcinoma Treatment in the Netherlands: An Analysis From the Netherlands Cancer Registry From 2014 to 2019
por: Steenaard, Rebecca, et al.
Publicado: (2021)

Innovative multidimensional models in a high-throughput-format for different cell types of endocrine origin
por: Bornstein, Stefan, et al.
Publicado: (2022)

Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues?
por: Sbiera, Iuliu, et al.
Publicado: (2021)

OR02-6 Mass Spectrometry-Based Steroid Profiling Inprimary Bilateral Macronodular Adrenocortical Hyperplasia
por: Hannah-Shmouni, Fady, et al.
Publicado: (2019)

Patient and Partner Perspectives on Health-Related Quality of Life in Adrenocortical Carcinoma
por: Steenaard, Rebecca V, et al.
Publicado: (2020)

Stimulated Expression of CXCL12 in Adrenocortical Carcinoma by the PPARgamma Ligand Rosiglitazone Impairs Cancer Progression
por: Cantini, Giulia, et al.
Publicado: (2021)

Steroid profiling using liquid chromatography mass spectrometry during adrenal vein sampling in patients with primary bilateral macronodular adrenocortical hyperplasia
por: Zhang, Ru, et al.
Publicado: (2022)

Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma
por: Chortis, Vasileios, et al.
Publicado: (2019)

A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma
por: Sigala, Sandra, et al.
Publicado: (2022)

FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma
por: Tamburello, Mariangela, et al.
Publicado: (2022)

Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma
por: Jouinot, Anne, et al.
Publicado: (2020)

Progress in Primary Aldosteronism 2019: New Players on the Block?
por: Reincke, Martin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1emrqt9mao5d76vs8mk5qohps5